Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: Results from the LixiLan-L-CN randomized controlled trial

Yuan, XY; Guo, XH; Zhang, JQ; Dong, XL; Lu, YB; Pang, WY; Gu, SH; Niemoeller, E; Ping, L; Nian, GW; Souhami, E

Guo, XH (通讯作者)，Peking Univ First Hosp, Beijing, Peoples R China.

DIABETES OBESITY & METABOLISM, 2022; 24 (11): 2182

Abstract

Aims To evaluate the efficacy and safety of iGlarLixi compared with iGlar in Chinese adults with type 2 diabetes advancing therapy from basal insulin ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索